Long Term Effects of an Early Response to Certolizumab Pegol (CZP, Cimzia®) in Rheumatoid Arthritis (RA) Patients
NCT01288287 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 149
Last updated 2016-09-16
Summary
To determine if early clinical response at 12 weeks to Certolizumab Pegol (CZP, Cimzia ®) therapy in adult Rheumatoid Arthritis (RA) patients is a predictor of better long term clinical response at 18 months compared with a lack of clinical response at 12 weeks.
Conditions
- Arthritis,Rheumatoid
Sponsors & Collaborators
-
UCB Pharma
lead INDUSTRY
Principal Investigators
-
UCB Clinical Trial Call Center · +1 877 822 9493 (UCB)
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2011-07-31
- Primary Completion
- 2014-10-31
- Completion
- 2014-12-31
Countries
- Ireland
- United Kingdom
Study Locations
More Related Trials
-
Rheumatoid Arthritis Treatment and Biopsy Study Assessing Certolizumab Pegol (Cimzia)
NCT01374971 ·Status: COMPLETED ·Phase: PHASE3
-
Open Label Long-Term Safety Study of Certolizumab Pegol (CZP) for Patients With Rheumatoid Arthritis
NCT00160693 ·Status: COMPLETED ·Phase: PHASE3
-
A Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drugs (DMARD)-naïve Adults With Early Active Rheumatoid Arthritis
NCT01519791 ·Status: COMPLETED ·Phase: PHASE3
-
Scintigraphic Detection of the Biodistribution of Tumor Necrosis Factor With a Radiolabeled Anti-TNFα in Patients With Active Rheumatoid Arthritis and Active Axial and Peripheral Spondyloarthritis
NCT01590966 ·Status: COMPLETED ·Phase: PHASE3
-
Can TNF-Alpha Incomplete Secondary Responders Attain a Safe and Efficacious Response Switching to Cimzia
NCT01147341 ·Status: COMPLETED ·Phase: PHASE4
-
A Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drugs (DMARD)-naïve Adults With Early Active Rheumatoid Arthritis
NCT01521923 ·Status: COMPLETED ·Phase: PHASE3
-
Open Label Study to Assess the Predictability of Early Response to Certolizumab Pegol in Patients With Rheumatoid Arthritis
NCT01443364 ·Status: COMPLETED ·Phase: PHASE4
-
National Data Bank for Rheumatic Disease Registry Study of Safety in Patients With Rheumatoid Arthritis Treated With Cimzia® or Disease-modifying Antirheumatic Drugs (DMARDs)
NCT01095393 ·Status: COMPLETED
-
Study to Assess the Short- and Long-term Efficacy of Certolizumab Pegol Plus Methotrexate Compared to Adalimumab Plus Methotrexate in Subjects With Moderate to Severe Rheumatoid Arthritis (RA) Inadequately Responding to Methotrexate
NCT01500278 ·Status: COMPLETED ·Phase: PHASE4
-
Cimzia Treatment in Rheumatoid Arthritis: Randomizing to Stop Versus Continue Disease-modifying Anti-rheumatic Drug(s)
NCT01489384 ·Status: UNKNOWN
-
A Study of the Safety and Effectiveness of Lyophilized Certolizumab Pegol in the Treatment of Signs and Symptoms of Rheumatoid Arthritis and in Prevention of Joint Damage in Patients With Active Rheumatoid Arthritis
NCT00175877 ·Status: COMPLETED ·Phase: PHASE3
-
IL-7 and IL-7R Expression in RA Patients With Active vs. Inactive Disease Treated With DMARD or CIMZIA
NCT02451748 ·Status: COMPLETED ·Phase: PHASE4
-
Efficacy Confirmation Study of CDP870 in Early Rheumatoid Arthritis
NCT01451203 ·Status: COMPLETED ·Phase: PHASE3
-
Named Patient Program With Certolizumab Pegol in Adults Suffering From Rheumatoid Aarthritis (RA)
NCT03559686 ·Status: AVAILABLE
-
A Placebo Controlled Study to Assess Efficacy and Safety of Certolizumab Pegol in the Treatment of Rheumatoid Arthritis
NCT00152386 ·Status: COMPLETED ·Phase: PHASE3
-
A Study to Assess the Pharmacokinetics of Certolizumab Pegol in Adults With Active Rheumatoid Arthritis
NCT04740814 ·Status: COMPLETED ·Phase: PHASE1
-
Certolizumab Pegol in Subjects With Adult Onset Active and Progressive Psoriatic Arthritis
NCT01087788 ·Status: COMPLETED ·Phase: PHASE3
-
A Study of Certolizumab Pegol as Additional Therapy in Chinese Patients With Active Rheumatoid Arthritis
NCT02151851 ·Status: COMPLETED ·Phase: PHASE3
-
Health-related Quality of Life and Patient-reported Outcomes in Rheumatoid Arthritis Patients Treated With Certolizumab Pegol
NCT01526434 ·Status: COMPLETED
-
Dosing Flexibility Study in Patients With Rheumatoid Arthritis
NCT00580840 ·Status: COMPLETED ·Phase: PHASE4
-
Impact of Anti-citrullinated Protein Antibody Status on Treatment Response and Treatment Persistence in Participants With Rheumatoid Arthritis (RA) Who Are Treated With Abatacept or Tumor Necrosis Factor Inhibitors in Australia
NCT03663829 ·Status: COMPLETED
-
Phase IIB Dose Ranging Study in Subjects With Moderate to Severe Rheumatoid Arthritis
NCT02015520 ·Status: COMPLETED ·Phase: PHASE2
-
Certolizumab Pegol in Subjects With Active Axial Spondyloarthritis
NCT01087762 ·Status: COMPLETED ·Phase: PHASE3
-
A Study of the Safety and Effectiveness of Liquid Certolizumab Pegol in the Treatment of Signs and Symptoms of Rheumatoid Arthritis and in Prevention of Joint Damage in Patients With Active Rheumatoid Arthritis
NCT00160641 ·Status: COMPLETED ·Phase: PHASE3
-
A Study to Assess the Effectiveness of Certolizumab Pegol in Patients With Axial Spondyloarthritis in Daily Life
NCT02354105 ·Status: COMPLETED